Here are the S-1 registration statements from Tivic Health Systems, Inc. (TIVC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow TIVC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TIVC filings page.
Tivic Health Systems, Inc. is registering 956,222 shares of common stock for resale by Tumim Stone Capital under an equity line arrangement. The shares include 519,210 shares that Tivic may sell to Tumim under a $50.0 million common stock purchase agreement and 437,012 shares issuable on exercise of a commitment pre-funded warrant.
Tivic will not receive proceeds from Tumim’s resale of these shares but may raise up to $50.0 million by selling stock to Tumim over 24 months, subject to ownership and Nasdaq exchange caps. If all 956,222 shares were issued, they would equal about 24.94% of the 3,834,148 shares assumed outstanding. The company has pivoted from bioelectronic devices to a late-stage biopharmaceutical focus around its TLR5 agonist Entolimod, launched CDMO subsidiary Velocity Bioworks, and executed significant reverse stock splits to maintain its Nasdaq listing.